The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q).

TitleThe Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q).
Publication TypeJournal Article
Year of Publication2019
AuthorsBelleville S, LeBlanc AC, Kergoat M-J, Calon F, Gaudreau P, Hébert SS, Hudon C, Leclerc N, Mechawar N, Duchesne S, Gauthier S
Corporate AuthorsConsortium for the Early Identification of Alzheimer's disease-Quebec(CIMA-Q)
JournalAlzheimers Dement (Amst)
Volume11
Pagination787-796
Date Published2019 Dec
ISSN2352-8729
Abstract

Introduction: The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia.Methods: CIMA-Q established standardized clinical, neuropsychological, neuroimaging, blood (plasma, serum, RNA, genomic DNA), cryopreserved peripheral blood mononuclear cells, and cerebrospinal fluid collection protocols. These data and biological materials are available to the research community.Results: In phase 1, 115 persons with subjective cognitive decline, 88 with mild cognitive impairment, 31 with early probable Alzheimer's disease, and 56 older adults with no worries nor impairments received detailed clinical and cognitive evaluations as well as blood and peripheral blood mononuclear cells collections. Among them, 142 underwent magnetic resonance imaging, 29 a fluorodeoxyglucose positron emission tomography, and 60 a lumbar puncture.Discussion: CIMA-Q provides procedures and resources to identify early biomarkers and novel therapeutic targets, and holds promise for detecting cognitive decline in Alzheimer's disease.

DOI10.1016/j.dadm.2019.07.003
Alternate JournalAlzheimers Dement (Amst)
PubMed ID31788534
PubMed Central IDPMC6880140